Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

[1]  A. Thompson,et al.  Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.

[2]  Mark Clemons,et al.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Goldhirsch,et al.  Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. , 2010, Clinical breast cancer.

[4]  T. Fehm,et al.  HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.

[5]  Ru-Fang Yeh,et al.  Molecular Biomarker Analyses Using Circulating Tumor Cells , 2010, PloS one.

[6]  F. Orsi,et al.  Should liver metastases of breast cancer be biopsied to improve treatment choice? , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Loda,et al.  Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer , 2010, British Journal of Cancer.

[8]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[9]  Annibale Biggeri,et al.  Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients , 2009, Breast Cancer Research and Treatment.

[10]  M. Dieci,et al.  Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. , 2008, The oncologist.

[11]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[12]  Sanjay Shete,et al.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.

[13]  D. Hayes,et al.  Comparison of HER-2 Overexpression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metastatic Disease , 2006 .

[14]  T. Fehm,et al.  Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients , 2006, Breast Cancer Research and Treatment.

[15]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[16]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[18]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[19]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Merkel,et al.  erbB-2 (HER-2) and Breast Cancer Progression , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  Jinha M. Park,et al.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Larsimont,et al.  Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Tanja Fehm,et al.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  D. Sargent,et al.  A three-outcome design for phase II clinical trials. , 2001, Controlled clinical trials.

[25]  C. Rao,et al.  Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. , 2000, International journal of oncology.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[29]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.